We are live on ! Find out more
BBIO icon

BridgeBio Pharma
BBIO

116 hedge funds and large institutions have $3.82B invested in BridgeBio Pharma in 2020 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 43 increasing their positions, 23 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,325% more call options, than puts

Call options by funds: $25.4M | Put options by funds: $743K

220% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 10

87% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 23

33% more funds holding in top 10

Funds holding in top 10: 6 → 8 (+2)

22% more funds holding

Funds holding: 95 → 116 (+21)

17% more capital invested

Capital invested by funds: $3.28B → $3.82B (+$548M)

5.36% more ownership

Funds ownership: 91.29% → 96.65% (+5.4%)

Holders
116
Holders Change
+21
Holders Change %
+22.11%
% of All Funds
2.38%
Holding in Top 10
8
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+33.33%
% of All Funds
0.16%
New
32
Increased
43
Reduced
23
Closed
10
Calls
$25.4M
Puts
$743K
Net Calls
+$24.7M
Net Calls Change
+$16.6M

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$104M
2
State Street
State Street
Massachusetts
+$44.9M
3
Citigroup
Citigroup
New York
+$21.1M
4
CS
Credit Suisse
Switzerland
+$16.4M
5
BlackRock
BlackRock
New York
+$10.2M

Top Sellers

Rank Fund Capital Flow
1
KKRC
Kohlberg Kravis Roberts & Co
New York
-$72.8M
2
CAM
Cormorant Asset Management
Massachusetts
-$10.9M
3
AIG
American International Group
New York
-$9.09M
4
Millennium Management
Millennium Management
New York
-$5.99M
5
WAM
Weiss Asset Management
Massachusetts
-$4.68M
Name Holding Trade Value Shares
Change 		Change in
Stake
NIP
51
Nicholas Investment Partners
California
$1.74M -$215K -7,068 -12%
MSL
52
Mackay Shields LLC
New York
$1.72M +$1.61M +52,700 New
PA
53
Pinnacle Associates
New York
$1.67M +$1.55M +51,044 New
PWMAG
54
Pinnacle Wealth Management Advisory Group
New Jersey
$1.67M +$1.55M +51,044 New
Wells Fargo
55
Wells Fargo
California
$1.54M +$273K +8,953 +23%
Citadel Advisors
56
Citadel Advisors
Florida
$1.53M +$445K +14,616 +45%
Ameriprise
57
Ameriprise
Minnesota
$1.53M -$356K -11,690 -20%
AQR Capital Management
58
AQR Capital Management
Connecticut
$1.52M +$1.42M +46,725 New
Barclays
59
Barclays
United Kingdom
$1.48M +$491K +16,124 +55%
Manulife (Manufacturers Life Insurance)
60
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.45M -$98.5K -3,235 -7%
Deutsche Bank
61
Deutsche Bank
Germany
$1.37M +$484K +15,903 +61%
Millennium Management
62
Millennium Management
New York
$1.29M -$5.99M -196,520 -83%
TCM
63
Tekla Capital Management
Massachusetts
$1.28M – – –
Principal Financial Group
64
Principal Financial Group
Iowa
$1.26M +$903K +29,660 +326%
Russell Investments Group
65
Russell Investments Group
United Kingdom
$1.13M +$1.05M +34,552 New
Rafferty Asset Management
66
Rafferty Asset Management
New York
$1.09M +$1.01M +33,309 New
MIM
67
MetLife Investment Management
New Jersey
$1.05M – – –
Allianz Asset Management
68
Allianz Asset Management
Germany
$1.01M -$754K -24,749 -44%
Dimensional Fund Advisors
69
Dimensional Fund Advisors
Texas
$1M -$111K -3,639 -11%
State Board of Administration of Florida Retirement System
70
State Board of Administration of Florida Retirement System
Florida
$1M +$465K +15,280 +99%
PPA
71
Parametric Portfolio Associates
Washington
$979K +$416K +13,651 +83%
ProShare Advisors
72
ProShare Advisors
Maryland
$955K +$240K +7,894 +37%
AC
73
Athanor Capital
New York
$944K +$882K +28,958 New
Susquehanna International Group
74
Susquehanna International Group
Pennsylvania
$922K -$516K -16,930 -37%
KPW
75
Kore Private Wealth
New York
$921K – – –
1 2
3
4 5

BBIO Hedge Fund Activity: Q2 2020 in Review

116 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q2 2020, worth a combined $3.82B — up 17% from $3.28B a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new BBIO positions and 10 closed out — a net gain of 22 holders — while 43 added to existing stakes and 23 trimmed.

The largest buyer was Vanguard Group, adding an estimated $104M. The largest seller was Kohlberg Kravis Roberts & Co, cutting an estimated $72.8M.

  • 116 institutional investors held BridgeBio Pharma (BBIO) as of Q2 2020, up from 95 in Q1 2020.
  • Funds reported $3.82B of BridgeBio Pharma stock for Q2 2020, up 17% quarter-over-quarter.
  • 32 funds opened new BridgeBio Pharma positions in Q2 2020 and 10 closed out, a net change of +22 holders.
  • The largest BridgeBio Pharma buyer in Q2 2020 was Vanguard Group, an estimated $104M added.
  • The largest BridgeBio Pharma seller in Q2 2020 was Kohlberg Kravis Roberts & Co, an estimated $72.8M sold.

Based on aggregated 13F filings for Q2 2020.